Developing strategies to enhance cancer prevention is a paramount goal, particularly given recent concerns about surgical treatment of preinvasive states such as ductal carcinoma in situ. Promoting effective immunosurveillance by leukocytes that scan for nascent neoplastic transformations represents a potential means to achieve this goal. Because most breast cancers arise within the ductal epithelium, enhancing protective immunosurveillance will likely necessitate targeting one or more of the distinctive lymphocyte types found in these sites under normal conditions. Here, we have characterized the intraepithelial lymphocyte compartment of non-cancerous human breast tissue and identified a subset of T lymphocytes that can be pharmacologically targeted to enhance their responses to breast cancer cells. Specifically, Vd2 þ gd T cells were consistently present in preparations of mammary ductal epithelial organoids and they proliferated in response to zoledronic acid, an aminobisphosphonate drug. Vd2 þ T cells from breast ductal organoids produced the antitumor cytokine IFNg and efficiently killed bisphosphonate-pulsed breast carcinoma cells. These findings demonstrate the potential for exploiting the ability of Vd2 þ gd T cells to respond to FDA-approved bisphosphonate drugs as a novel immunotherapeutic approach to inhibit the outgrowth of breast cancers.
Introduction
Identifying genetic loci associated with reduced risk of breast cancer may provide novel targets for cancer prevention (1) . Such loci may operate directly within mammary epithelial cells or may be mediated by the activities of non-mammary cells. We have recently reported that the rat Mcs5a locus acts via the immune system and that the resistant allele of Mcs5a is associated with increased frequency and functional activity of gd T cells within spleen and mammary epithelium (2) . These findings suggest that engaging key immune cell types to phenocopy the effects of the resistant Mcs5a allele may represent an effective breast cancer prevention strategy. However, given the substantial differences between humans and muroid rodents in the molecular specificities of innate immune cells that mediate defense against incipient threats, an essential prerequisite to such an effort is identifying the immune subsets typically present in human mammary ductal epithelial tissues and determining how these can be medically targeted.
Cancerous cells are culled from tissues through the process of immunosurveillance, whereby several different types of leukocytes continuously scan for neoplastically transformed cells and eliminate them (3) . Because breast cancers typically originate from the epithelial cells lining the mammary ducts and lobules (4) , the immune cells responsible for immunosurveillance of transformed breast cells are likely to be those that patrol the ductal epithelium. Although recent studies have illustrated the presence of leukocytes in the human breast (5) (6) (7) (8) and even in the epithelium (6, 7) , the specific leukocyte subsets within this specialized tissue niche have remained poorly characterized. Moreover, a key unanswered question is whether immune cells are present that can be targeted to promote enhanced immunosurveillance of precancerous or cancerous cells.
Conserved T lymphocyte populations are particularly attractive for this type of approach because they recognize non-polymorphic antigen-presenting molecules and thus are present in all individuals regardless of human leukocyte antigen (HLA) type, and they can selectively be activated based on features of the T cell receptor (TCR). Some examples of conserved T lymphocytes are gd T cells, mucosal-associated invariant T (MAIT) cells, and invariant natural killer T (iNKT) cells. Based on their characteristic TCR chain usages, these types of T cells can be specifically targeted using monoclonal antibodies (mAb), or in some cases by synthetic compounds.
For example, human Vd2
þ T cells are selectively activated by FDA-approved aminobisphosphonate (BP) drugs. These compounds act on Vd2 þ T cells because they block the mevalonate biosynthetic pathway within target cells, which leads to the accumulation of a particular metabolic intermediate called isopentenylpyrophosphate (IPP) . IPP associates with the cytoplasmic tail of a cell-surface protein called butyrophilin 3A1 (BTN3A1), causing a recognizable change in molecular features of the extracellular domain of BTN3A1 (9, 10) . Target cells that express BTN3A1 and that have undergone an intracellular accumulation of IPP trigger TCR-dependent activation of Vd2 þ T cells (11) (12) (13) , causing them to proliferate, secrete cytokines such as IFNg, and to kill the target cells (14) . Thus, BPs may promote the antitumor functions of human gd T cells in several ways, including (i) by expanding the numbers of Vd2 þ T cells;
(ii) by promoting their production of the antitumor cytokine IFNg; and (iii) by promoting their killing of tumor cells. Indeed, administration of BPs to human cancer patients who had bone metastases (3 females with breast cancer and 6 males with prostate cancer) was associated with the expansion of an effector population of Vd2 þ T cells in the blood, and with enhanced IFNg production (15 
Materials and Methods
Breast tissue acquisition and preparation Non-cancerous breast tissue was obtained from the Cooperative Human Tissue Network (CHTN; funded by the National Cancer Institute) or provided by the University of Wisconsin's Translational Science BioCore-BioBank from reduction mammoplasties or contralateral prophylactic mastectomies (Table 1) . Acquisition and analysis of the breast tissue was approved by the University of Wisconsin Health Services Institutional Review Board.
Human breast organoids were isolated as previously published (22, 23) . Briefly, breast tissue was minced and digested overnight in a 37 C shaker with 1X collagenase/hyaluronidase in Complete EpiCult B Human Media (Stem Cell Technologies) supplemented with 5% fetal bovine serum (FBS; Hyclone). After incubation, the digested tissue was spun for 1 minute or less at 80 to 100 Â g to form a visible cell pellet enriched for epithelial ductal organoids. This cell pellet was washed and the breast organoids were collected on a 40-mm filter. In addition, a cell pellet containing stromal cells, red blood cells and small ductal epithelial fragments was also collected from the supernatant of the digested tissue. Organoids and stromal cell fractions were cryopreserved in 50% FBS/6% dimethyl sulfoxide, and stored in liquid nitrogen until needed. Single-cell suspensions from the organoids were prepared for all flow cytometric analyses and used for in vitro experiments by trypsinizing the organoids using 2 mL of ethylenediaminetetraacetic acid (EDTA)/trypsin solution for 1 to 2 minutes. EDTA (Thermo 
Bisphosphonate stimulation and Vd2 T cell expansion
PBMCs or single cells prepared from the breast organoids were exposed to 2.5 mmol/L zoledronate in combination with irradiated feeder PBMCs (exposed to 7 Â 10 3 to 8 Â 10 3 Rad) to stimulate and expand Vd2 gd T cells. Specifically, 2 Â 10 5 isolated PBMCs were cultured with 5 Â 10 5 irradiated feeders in an end volume of 0.2 mL T cell media in 96-well plates. Single-cell preparations from organoids were plated with 5 Â 10 5 total irradiated feeders in an end volume of 0.2 mL T cell media in 96-well plates. Lymphocyte cultures were maintained in RPMI 1640 with L-glutamine (Corning) supplemented with 15% heat inactivated bovine calf serum (HI-BCS; Thermo Fisher Scientific), 3% human AB serum (Atlanta Biologicals), 1% penicillin/streptomycin (P/S; Mediatech) and 200 units/mL IL2 (Peprotech) referred to as T cell media. Percentages of Vd2 T cells were obtained by flow cytometry 2 to 3 weeks after stimulation and compared with media-only controls; Vd2 frequencies above 1% were considered positive for expansion. Alternately, freshly isolated PBMCs were also stimulated with 2.5 mmol/L zoledronate in T cell media at 1 Â 10 6 cells/well in 24-well plates and expanded for 7 days. Bisphosphonate (BP) expanded cells were used in cytotoxicity assays. BP dose response curves were generated using fresh PBMCs with either zoledronate or alendronate for 7 days in T cell media. Fresh media were provided when needed. Zoledronate (Novation LLC and Novartis) and alendronate (Teva Pharmaceuticals USA) BP were obtained from UW Health Pharmacy Services.
Analysis of Vd2
þ T cell responses to tumor cells MDA-MB-468 breast carcinoma cells were obtained from ATCC as an authenticated cell line, and maintained in DMEM/F12 (Corning) supplemented with 10% HI-BCS (Thermo Fisher Scientific) and 1% P/S (Mediatech). The MDA-MB-468 cells were pulsed with or without 5 mmol/L zoledronate overnight, then washed and resuspended at 3 Â 10 6 cells/1.0 mL media. Cells from primary organoids and cell suspensions containing BP expanded organoid-or blood-derived Vd2 T cells were each incubated with MDA-MB-468 cells for 4 to 6 hours at 37 C in a total of 0.2 mL in 96-well plates. After the incubation, Vd2 T cells were analyzed for cell-surface LAMP-1 and/or intracellular IFNg expression by flow cytometry.
To assess gd T cell killing of target cells, MDA-MB-468 cells were used as targets and day 7 BP expanded PBMC-derived Vd2 T cells were used as effectors. Briefly, targets were pulsed with or without 10 mmol/L zoledronate overnight. At the same time, day 7 stimulated Vd2 T cells were cultured with IL2 overnight. The following day, targets were trypsinized, washed and prepared at a concentration of 1Â 10 5 to 2 Â 10 5 cells/0.1 mL T cell media without IL2. Effectors were prepared without IL2 and co-incubated with targets at different effector-to-target ratios in 96-well plates at 37 C for 4.5 hours. Additionally, 0.1 mLs of 0.1% trypsin was used for several minutes to recover adherent cells. The cells were washed with Fc block and stained with CD45 for 30 minutes at 4 C to delineate effectors from targets. Samples were washed with PBS, spun, and resuspended in Annexin V binding buffer (BioLegend). Annexin V (5 mL/tube; BioLegend) and propidium iodide (10 mL/tube; BioLegend) were added to samples and incubated for 15 minutes in the dark at room temperature. Additional Annexin V binding buffer was added before flow cytometry analysis.
Statistical analysis
GraphPad Prism versions 4.0 and 4.0c software (GraphPad Software) were used to construct data graphs and determine statistical significance using the Wilcoxon test for paired samples or the Student unpaired two-tailed t test or the Mann-Whitney. The P value cutoffs and notation were used as follows: Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P 0.0001.
Results
Preparation of human breast tissue yields highly enriched ductal epithelial organoids Samples of breast tissue from human subjects who had undergone reduction mammoplasty or prophylactic mastectomy were collected for analysis (see Table 1 ). The samples were prepared using a protocol designed to separate tissue fragments representing ductal organoids from stromal layers. A representative image of the resulting tissue fragments showing ductal and alveolar structures is shown in Fig. 1A . To confirm that the fragment preparations were enriched for epithelial cells compared with the stromal fraction, we utilized multiparameter flow cytometry to assess relative frequencies of cells expressing epithelial, endothelial, or hematopoietic markers (Fig. 1B) . Cells that were double negative for both the hematopoietic linage marker CD45 and the endothelial marker platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31; ref. 24) were Characterization of immune cells from breast-derived organoids yields unique lymphocyte percentages compared with blood. A, gating strategy to delineate CD3 Fig. S1A-S1E) . Organoid preparations contained an average of 24% CD45 þ cells (leukocytes), and 9% CD31 þ cells (endothelial cells; ref. Fig. 1D ). These results indicated that our breast tissue preparation method successfully enriches for ductal epithelial organoids, and thus the associated leukocytes are likely to be highly enriched for cells from the ductal epithelial tissue.
Leukocyte populations associated with human breast organoids differ from those in peripheral blood We next examined the immune cell subsets within the CD45 þ population of the breast organoid preparations. Typically, at least 90% (90.63% AE 7.51%) of the CD45 þ cells were CD3 þ , indicating that they are T lymphocytes ( Fig. 2A and B) . In contrast, CD3
þ cells made up on average about 60% of the CD45 þ cells in the peripheral blood ( Fig. 2A and 2B Fig. 2E and F) . Moreover, typically 80% (AE12.94%) of the organoid preparation CD8 þ T cells expressed the integrin a E (CD103), which is a marker of intraepithelial lymphocytes (30) , whereas less than 3% of the peripheral blood CD8 þ T cells expressed this marker ( Fig. 2G and H) Fig. S2C and S2D ), which is characteristic of a regulatory T cell phenotype. Notably, in contrast to the CD8 þ T cells, only a small fraction of organoid-derived CD4 þ T cells expressed CD103 (Supplementary Fig. S2E ). Together, these data demonstrate that the immune cell populations associated with our organoid preparations are clearly distinct from those of the blood, and are highly enriched for T cells with characteristics of IELs.
Conserved T lymphocyte subsets are present in organoids and expand in response to BP We next wanted to determine whether we could detect lymphocyte subsets with conserved T cell receptors within the breast organoids that might be targetable in a chemoprevention strategy against breast cancer. We screened for two different subpopulations of gd T cells (Vd1 and Vd2), MAIT cells, and iNKT cells. Both subsets of gd T cells were clearly detectable in almost all of the samples analyzed (Fig. 3A and B) , although they made up comparatively small percentages of the CD3 þ cells (Vd1 mean ¼ 1.27%; Vd2 mean ¼ 0.42%). MAIT cells, which were identified using the Va7.2 T cell receptor, were detectable as >3.1% of the CD3 þ cells in organoids (Fig. 3A and B). iNKT cells were detected in some of the samples, but did not appear to be markedly enriched (data not shown). Thus, although Vd2 cells are predominantly found within the blood, these results indicated that these potentially targetable T lymphocytes are typically present in the breast ductal epithelium. We next investigated whether breast epithelial organoid Vd2 þ T cells are able to respond functionally to an FDA-approved BP. Preliminary studies confirmed that zoledronate more potently stimulated blood-derived Vd2 þ T cells compared with alendronate ( Supplementary Fig. S3 ), consistent with prior studies by other groups (15, 31) . Therefore, we cultured the total cells from organoid preparations with zoledronate or with medium alone for 2 to 3 weeks, and performed flow cytometric analysis to determine the relative frequencies within the culture of Vd2 þ T cells or MAIT cells as a control. Exposure to BP resulted in marked increases in the frequency of Vd2 þ cells, but not of MAIT cells, within the cultures (Fig. 3C) . Increases in total Vd2 þ cell number were also observed, suggesting that the Vd2 þ T cells had proliferated (data not shown). Overall, exposure to BP induced clearly detectable Vd2 þ T cell expansion in approximately 45% of the organoid samples we tested (Fig. 3D ). These data demonstrate that organoid-derived Vd2 þ T cells can respond to an FDAapproved BP drug.
BP treatment facilitates IFNg production by organoid-derived Vd2 þ T cells in response to triple-negative breast carcinoma cells Whereas gd T cells typically have a T helper 1 (T H1 ) cytokine production phenotype that is characterized by the production of high levels of IFNg, it has recently become clear that lymphoid cells in and around epithelial tissues are also responsible for the production of IL17, a cytokine that promotes epithelial integrity but that may also play a pathogenic role in tumorigenesis (32) . Therefore, we tested cytokine production by primary T cells in organoid preparations by stimulating them with PMA and ionomycin, then performing intracellular cytokine staining for IFNg and IL17. Detectable populations of cells expressing IL17 were observed in the non-Vd2 CD8 þ and CD8 À T cell subsets; however, the Vd2 þ T cell population appeared heavily biased toward production of IFNg with little or no evidence of IL17-producing cells ( Supplementary  Fig. S4 ). Based on these results, we focused our further analyses on IFNg production. We determined whether the organoid-derived Vd2 þ T cells produce cytokines in response to a human breast carcinoma cell line, MDA-MB-468, which is triple negative for estrogen receptor, progesterone receptor, and HER2/neu. Organoid cells were cultured with BP for 3 to 4 weeks, then exposed to MDA-MB-468 cells that were either pulsed with BP or mock-treated. Intracellular cytokine staining was performed to detect the frequency of gd T cells expressing IFNg. We observed robust Breast organoids contain specifically targetable lymphocytes that respond to an FDA-approved BP drug. A, flow cytometry analysis of an organoid preparation from tissue sample L1 (see Table 1 ) for gd T cells and MAIT cells (Va7.2 T cell receptor). B, quantification of T cell subsets from organoid preparations from the indicated tissue samples (see Table 1 IFNg responses to BP-pulsed target cells, but little or no detectable IFNg staining in response to mock-treated target cells (Fig. 4A) . These results demonstrated that organoid-derived Vd2 þ T cells that expand in response to BP treatment also produce cytokines in response to BP-pulsed breast cancer cells, but did not clarify whether a significant frequency of the primary gd T cells within breast organoids can mount similar responses to transformed cells. Therefore, we tested the ability of primary Vd2 þ T cells within organoid cell preparations to produce cytokines in response to tumor cells directly ex vivo. Indeed, when we exposed organoidderived cells to BP-pulsed or mock-treated MDA-MB-468 breast carcinoma cells, we found that a detectable fraction of the Vd2 þ subset showed intracellular IFNg staining (Fig. 4B) . Analysis of multiple different primary tissue samples revealed that the normalized IFNg mean fluorescence intensity of the Vd2 þ cells was consistently higher in response to BP-pulsed MDA-MB-468 breast carcinoma cells than to mock-treated carcinoma cells (Fig. 4C ). These results demonstrate that primary gd T cells from breast ductal epithelia are able to respond functionally to breast carcinoma cells that have been exposed to BP.
Organoid-derived Vd2 þ T cells demonstrate cytotoxicity to
BP-treated triple-negative breast carcinomas
To further investigate, we tested the cytotoxic responses of Vd2 typically also showed cell-surface LAMP-1 expression in response to mock-treated target cells (Fig. 5A ). To confirm that Vd2 þ T cell surface LAMP-1 expression was correlated with target cell killing, we assessed the viability of the MDA-MB-468 carcinoma cells by Annexin V staining. BP-pulsed MDA-MB-468 carcinoma cells were efficiently killed upon exposure to in vitro--expanded Vd2 þ T cell cultures (greater than 75% target cell death within 4 hours; Fig. 5B ). Notably, there was also significant killing of mock-treated MDA-MB-468 breast carcinoma cells, although this required much higher effector-to-target cell ratios (Fig. 5B) . Analysis of T cells within primary organoid cell preparations revealed that a fraction of the Vd2 þ cells typically showed cell-surface LAMP-1 expression after exposure to MDA-MB-468 cells (Fig. 5C ). 50% of the samples (Fig. 5D ). (34) . We therefore investigated the expression of these key tumor control molecules. Flow cytometric analysis of the MDA-MB-468 cells revealed weakly positive staining for BTN3A1 (Fig. 6A) . Staining for expression of NKG2D ligands showed clearly positive staining for MICA/B and at least one member of the ULBP family (Fig. 6A) .
We also analyzed the organoid-derived lymphocytes for expression of the NKG2D receptor, and found that nearly all Vd2 þ and CD8 þ T cells, and some of the CD8 À T cells were NKG2D positive (Fig 6B) . Thus, most primary breast epithelial organoid associated T cells express receptors for recognition of stressed or neoplastic cells.
Discussion
It has recently become clear that the role of gd T cells in cancer can include both antitumorigenic and protumorigenic functions. Anti-neoplastic functions of gd T cells include their critical role in tumor immunosurveillance and as early responders to nascent transformations (35) (36) (37) . Additionally, gd T cells can mediate rejection (killing) of established tumors (38, 39) . Paradoxically, however, studies from murine models have indicated that gd T cells can also promote the outgrowth of carcinomas as a result of the expression of factors that promote epithelial cell growth (40) . Moreover, a recent analysis of human breast cancer patients showed that the presence of regulatory gd T cells within the tumor was correlated with poor survival and high risks of relapse (41) . These contrasting roles of gd T cells underscore that it is critical to understand the characteristics of the immune cells in ductal epithelial tissues in order to design effective immunopreventative strategies.
Prior analyses of immune populations associated with human breast have utilized unfractionated breast tissue that was not enriched specifically for the epithelial compartment. For example, Ruffell and colleagues analyzed tissue samples from prophylactic mastectomies and found that 60% to 70% of CD45 þ cells were CD3 þ T lymphocytes of several different varieties (5). The results presented here contrast with earlier studies of breast tissue and demonstrate that the human breast epithelial organoid represents a specialized immunological niche that is comprised mainly of T cells (>90% of the CD45 þ cells). In contrast to the composition of T cells from blood, the breast epithelial T cell population was markedly skewed toward CD8 þ cells, which is consistent with a recent study demonstrating that CD8 T cells are directly integrated within the breast epithelium (7). Moreover, our observation that both the CD4 þ and CD8 þ T cells from the breast organoids had a CD27 À effector memory phenotype contrasts sharply with the dominant phenotypes of T cells from blood. Thus, our analysis clearly establishes that a distinct make-up of leukocyte subsets is associated with the breast epithelial organoids, and that blood contamination of the samples is not a major factor. Given this, it was particularly noteworthy that we detected Vd2 þ T cells in 87% of organoids. This gd T cell subset is thought to localize mainly to the blood, while other types of gd T cells (e.g., Vd1 þ T cells) are thought to be characteristic of peripheral tissues (42 showed a less potent, but still significant cytotoxic response to the tumor cells that were not treated with BP (an effect that might be due to endogenous accumulation of IPP within the tumor cells, or simply to their upregulation of MICA/B molecules), it may be sufficient to use BP administration as a means to induce the proliferation of Vd2 þ T cells and thus to increase their frequency in vivo, without actually targeting breast epithelial cells for BP uptake.
In addition to Vd2 þ cells, we also detected Vd1 þ T cells in the breast epithelial organoid fraction. Vd1 cells have been shown to be highly antitumorigenic to different tumors such as multiple myeloma (44), acute myeloid leukemia (45) , and acute lymphoblastic leukemia (45) . As a result of recent advances in understanding molecular interactions involved in activating Vd1 þ T cells, such as CD1d-mediated presentation of the cellular lipid sulfatide (46) , it may soon be feasible to specifically target this subset. We also detected a subset of Va7.2 TCR expressing lymphocytes that have been broadly characterized as MAIT cells (47) . MAIT cells recognize vitamin metabolites that are presented by the non-classical antigen-presenting molecule MR-1 (47) . Because many different microbes produce the chemical compounds recognized by MAIT cells, including Staphylococcus aureus and epidermidis, which are the major causative agents for human mastitis, it is likely that there is an important interplay between the resident microbiota and the immune cells in the ductal networks of human breast.
Together, our findings demonstrate that the lymphocyte compartment associated with human breast ductal epithelial organoids contains several conserved T cell populations that could be targeted, or in some cases possibly inhibited, to promote the immune-mediated clearance of nascent neoplastic cells. Such an approach may be particularly important for prophylactically treating women thought to be at high risk for breast cancer, and may also provide a novel non-invasive means to treat ductal carcinoma in situ.
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